Expertise in
11
conditions

Dr. Kevin Schuler

Oncology
St Elizabeth Medical Center Inc
1 Medical Village Dr, 
Edgewood, KY 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
11
conditions
St Elizabeth Medical Center Inc
1 Medical Village Dr, 
Edgewood, KY 

Overview

Kevin Schuler is an Oncologist in Edgewood, Kentucky. Dr. Schuler is highly rated in 11 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Hernia Surgery, and Lymphadenectomy.

His clinical research consists of co-authoring 7 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in OH

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO

Locations

St Elizabeth Medical Center Inc
1 Medical Village Dr, Edgewood, KY 41017
Other Locations
Trihealth W LLC
10550 Montgomery Rd Ste 22, Montgomery, OH 45242

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Enrollment Status: Recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
Enrollment Status: Completed
Publish Date: December 18, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)
Enrollment Status: Unknown
Publish Date: December 29, 2021
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
View 10 Less Clinical Trials

7 Total Publications

Patient perspectives of telemedicine in gynecologic oncology during COVID.
Patient perspectives of telemedicine in gynecologic oncology during COVID.
Journal: Gynecologic oncology reports
Published: July 12, 2022
Similar Doctors
Expertise in
22
conditions
Dr. Kasiani Myers
Hematology | Oncology
Expertise in
22
conditions
Dr. Kasiani Myers
Hematology | Oncology

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (1.0 miles away)
513-636-4266
Languages Spoken:
English
See accepted insurances

Kasiani Myers is a Hematologist and an Oncologist in Cincinnati, Ohio. Dr. Myers is highly rated in 22 conditions, according to our data. Her top areas of expertise are Shwachman-Diamond Syndrome, Congenital Aplastic Anemia, Fanconi Anemia, Aplastic Anemia, and Bone Marrow Transplant.

Expertise in
17
conditions
Dr. Theodosia Kalfa
Hematology | Oncology
Expertise in
17
conditions
Dr. Theodosia Kalfa
Hematology | Oncology

Office

3333 Burnet Ave # 7015, 
Cincinnati, OH 
 (1.0 miles away)
513-636-4266
Languages Spoken:
English
See accepted insurances

Theodosia Kalfa is a Hematologist and an Oncologist in Cincinnati, Ohio. Dr. Kalfa is highly rated in 17 conditions, according to our data. Her top areas of expertise are Hereditary Spherocytosis, Hereditary Pyropoikilocytosis, Hemolytic Anemia, Congenital Hemolytic Anemia, and Splenectomy.

Expertise in
23
conditions
Dr. Stella Davies
Hematology | Oncology
Expertise in
23
conditions
Dr. Stella Davies
Hematology | Oncology

Office

3333 Burnet Ave # 7015, 
Cincinnati, OH 
 (1.0 miles away)
513-636-4266
Languages Spoken:
English
See accepted insurances

Stella Davies is a Hematologist and an Oncologist in Cincinnati, Ohio. Dr. Davies is highly rated in 23 conditions, according to our data. Her top areas of expertise are Congenital Aplastic Anemia, Fanconi Anemia, Shwachman-Diamond Syndrome, Bone Marrow Transplant, and Bone Graft.

Frequently Asked Questions about Dr. Kevin Schuler

How do I make an appointment with Dr. Kevin Schuler?

You can book an appointment with Dr. Kevin Schuler by calling their office at 859-301-2237. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kevin Schuler a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kevin Schuler is classified as an Distinguished expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kevin Schuler specialize in?

While Dr. Kevin Schuler is a Oncology, they have specific expertise in Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Endometrial Stromal Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Kevin Schuler participate in research or clinical trials?

Yes. Dr. Kevin Schuler has published 7 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Kevin Schuler's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kevin Schuler accept my insurance?

Dr. Kevin Schuler accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 859-301-2237 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schuler's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile